HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Featuring an interview with Dr Erika Hamilton, including the following topics: General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00) Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11) Mechanisms of resistance to endocrine therapy (10:08) Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26) Other applications for PROTACs (24:24) Emerging data from the Phase III evERA trial (27:38) Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51) CME information and select publications